pLC-Flag-UBE2G1 sg2R-P2A-Hygro
(Plasmid
#124299)
-
PurposeLentiviral vector for expression of Flag tagged UBE2G1-P2A-Hygro casette from a CMV promoter. UBE2G1 cDNA contains silent mutations to disrupt a sgRNA binding site.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 124299 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLCE
- Total vector size (bp) 8082
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersHygromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameUBE2G1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)534
-
Mutationseveral silent mutations to disrupt sgRNA targeting
-
GenBank IDNM_003342
-
Entrez GeneUBE2G1 (a.k.a. E217K, UBC7, UBE2G)
- Promoter CMV
-
Tag
/ Fusion Protein
- Flag (N terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer -
- 3′ sequencing primer - (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byUBE2G1 cDNA was cloned from Addgene plasmid 31407
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLC-Flag-UBE2G1 sg2R-P2A-Hygro was a gift from Eva Gottwein (Addgene plasmid # 124299 ; http://n2t.net/addgene:124299 ; RRID:Addgene_124299) -
For your References section:
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Patil A, Manzano M, Gottwein E. Blood Adv. 2019 Jul 23;3(14):2105-2117. doi: 10.1182/bloodadvances.2019031732. 10.1182/bloodadvances.2019031732 PubMed 31300418